Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in Pediatric Subjects With Moderate-to-Severe Atopic Dermatitis
NCT07660835Phase 2Recruiting
- Sponsor
- Galderma
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of nemolizumab in atopic dermatitis (AD), sponsored by Galderma. Started Jul 2026; status: recruiting.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07660835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07660835.